PineStone Asset Management Inc. Sells 4,500 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• PineStone Asset Management trimmed its Medpace stake by 15.4% in Q4, selling 4,500 shares and now holds 24,700 shares (about 0.09% of the company) valued at roughly $13.87 million.
• Insider selloff: President Jesse J. Geiger sold 31,707 shares on March 17 at an average $455.30 for about $14.44 million, reducing his holdings by 67.9% to 15,000 shares; insiders own ~20.3% of the stock.
• Fundamentals & outlook: Medpace beat quarterly estimates with $4.67 EPS and $708.45M revenue (revenue +32% YoY), provided FY2026 EPS guidance of 16.68–17.50, and carries a MarketBeat consensus rating of "Hold" with a $486.67 price target.

PineStone Asset Management Inc. trimmed its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 15.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 24,700 shares of the company's stock after selling 4,500 shares during the period. PineStone Asset Management Inc. owned 0.09% of Medpace worth $13,873,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of MEDP. Quent Capital LLC purchased a new position in shares of Medpace during the third quarter valued at about $25,000. Optiver Holding B.V. purchased a new stake in shares of Medpace in the third quarter worth about $27,000. Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after buying an additional 37 shares in the last quarter. Quarry LP bought a new position in Medpace during the third quarter valued at approximately $35,000. Finally, Root Financial Partners LLC bought a new position in Medpace during the third quarter valued at approximately $38,000. Hedge funds and other institutional investors own 77.98% of the company's stock.

Insider Buying and Selling

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the business's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the transaction, the president owned 15,000 shares in the company, valued at $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 20.30% of the stock is owned by insiders.

Medpace Price Performance

Shares of MEDP stock opened at $480.19 on Wednesday. The company has a market cap of $13.63 billion, a PE ratio of 31.38, a price-to-earnings-growth ratio of 2.21 and a beta of 1.44. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $628.92. The stock's 50 day simple moving average is $488.61 and its two-hundred day simple moving average is $537.50.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping analysts' consensus estimates of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The firm had revenue of $708.45 million during the quarter, compared to analysts' expectations of $689.53 million. During the same quarter in the previous year, the business earned $3.67 EPS. The company's quarterly revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Mizuho set a $582.00 price objective on Medpace in a research note on Wednesday, February 11th. Royal Bank Of Canada began coverage on Medpace in a research report on Tuesday, March 3rd. They set an "outperform" rating and a $522.00 target price for the company. Robert W. Baird upgraded shares of Medpace from a "neutral" rating to an "outperform" rating and set a $564.00 price target on the stock in a research report on Tuesday, February 10th. Wall Street Zen raised shares of Medpace from a "hold" rating to a "buy" rating in a research note on Saturday, January 17th. Finally, TD Cowen upgraded shares of Medpace from a "sell" rating to a "hold" rating and lowered their price objective for the company from $462.00 to $419.00 in a research report on Wednesday, February 18th. Five analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $486.67.

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.